Skip to Main Content

This was supposed to be the microbiome’s breakthrough year — and pandemic or not, it looks like it still might be.

Three companies — Finch Therapeutics, Seres Therapeutics, and Rebiotix — said earlier this year that they expected to announce results from pivotal clinical trials for recurrent C. difficile treatments sometime this summer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!